Cliff Asness's CLDX Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 7,777 shares of Celldex Therapeutics, Inc. (CLDX) worth $246,687, representing 0.00% of the portfolio. First purchased in 2021-Q3, this medium-term investment has been held for 15 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in CLDX, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2024, adding 17,486 shares. Largest reduction occurred in Q1 2025, reducing 21,724 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Celldex Therapeutics (CLDX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Celldex Therapeutics (CLDX) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +7,777 | New Buy | 7,777 | $31.72 |
| Q1 2025 | -21,724 | Sold Out | 0 | $0.00 |
| Q4 2024 | -3,619 | Reduce 14.28% | 21,724 | $25.27 |
| Q3 2024 | +17,486 | Add 222.55% | 25,343 | $33.99 |
| Q2 2024 | +1,504 | Add 23.67% | 7,857 | $37.01 |
| Q1 2024 | +6,353 | New Buy | 6,353 | $41.97 |
| Q3 2023 | -6,835 | Sold Out | 0 | $0.00 |
| Q2 2023 | +5 | Add 0.07% | 6,835 | $33.93 |
| Q1 2023 | -1,738 | Reduce 20.28% | 6,830 | $35.98 |
| Q4 2022 | -660 | Reduce 7.15% | 8,568 | $44.57 |
| Q3 2022 | -232 | Reduce 2.45% | 9,228 | $28.07 |
| Q4 2021 | -1,392 | Reduce 12.83% | 9,460 | $38.69 |
| Q3 2021 | +10,852 | New Buy | 10,852 | $54.00 |
Cliff Asness's Celldex Therapeutics Investment FAQs
Cliff Asness first purchased Celldex Therapeutics, Inc. (CLDX) in Q3 2021, acquiring 10,852 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Celldex Therapeutics, Inc. (CLDX) for 15 quarters since Q3 2021.
Cliff Asness's largest addition to Celldex Therapeutics, Inc. (CLDX) was in Q3 2024, adding 25,343 shares worth $861,409.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 7,777 shares of Celldex Therapeutics, Inc. (CLDX), valued at approximately $246,687.
As of the Q1 2026 filing, Celldex Therapeutics, Inc. (CLDX) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Celldex Therapeutics, Inc. (CLDX) was 25,343 shares, as reported at the end of Q3 2024.